Andrew Luber Email & Phone Number

Philadelphia, Pa, Us

Virion Therapeutics, LLC, is a science-driven company whose mission is to cure cancer and chronic infectious diseases through the development of novel and accessible CD8+ T cell-based immunotherapies. Our proprietary technologies combine genetically encoded checkpoint modifiers, with selected and optimized target-specific antigens, that are delivered within a highly immunogenic and adaptable viral vector platform which promote potent, prolonged, and broad CD8+ T cell responses. Virion was founded in early 2018 to advance technology licensed from The Wistar Institute, an international leader in biomedical research with specific expertise in vaccine, cancer and infectious disease research. Combined with this foundation, Virion has developed a best-in-class, experienced biotechnology management team which is augmented by a global advisory board with extensive preclinical and clinical expertise in antiviral, vaccine, and immuno-oncology. Our lead VRON-0200 program for treatment of Chronic Hepatitis B Virus is scheduled for the clinic at the end of 2022.www.VirionTx.com

Virion Therapeutics, LLC, is a science-driven company whose mission is to cure cancer and chronic infectious diseases through the development of novel and accessible CD8+ T cell-based immunotherapies. Our proprietary technologies combine genetically encoded checkpoint modifiers, with selected and optimized target-specific antigens, that are delivered within a highly immunogenic and adaptable viral vector platform which promote potent, prolonged, and broad CD8+ T cell responses. Virion was founded in early 2018 to advance technology licensed from The Wistar Institute, an international leader in biomedical research with specific expertise in vaccine, cancer and infectious disease research. Combined with this foundation, Virion has developed a best-in-class, experienced biotechnology management team which is augmented by a global advisory board with extensive preclinical and clinical expertise in antiviral, vaccine, and immuno-oncology. Our lead VRON-0200 program for treatment of Chronic Hepatitis B Virus is scheduled for the clinic at the end of 2022.www.VirionTx.com

Moerae Matrix develops innovative therapies for patients suffering from inflammatory and fibrotic disorders via a pipeline of novel first-in-class peptide based MAPKAP Kinase 2 (MK2) inhibitors. Key roles included helping to advance the lead candidate (MMI-0100) into the clinic and through 3 Phase 1 clinical trials for treatment of Idiopathic Pulmonary Fibrosis as well as continued advancement of the pipeline peptides through preclinical development.

Clinical consultant to various pharmaceutical companies, advertising agencies, vendors and medical education groups in the areas of antiviral drug development, medical education and on-label promotional pieces. In addition, performed numerous investigator initiated research studies in the areas of HIV/HCV as a Consultant to Garden State Infectious Diseases in Voorhees NJ.

- Responsible for the procurement, contract/study budget, and oversight of more than 40 Phase I-III clinical trials, including 4 Ia first in human studies.- Development, procurement, implementation, evaluation and presentation/publication of 15 investigator initiated Phase IV studies. - Management and oversight of day-to-day functions of large private practice research centers, including staffing, budgetary and regulatory issues.

Pharmd, Infectious Diseases Pharmacotherapy Fellowship

Pharm.D, Residency In Infectious Diseases

Pharmd, Residency

Pharmd

Bs. Pharm.